0
2021
Rapid Acting Insulin Market

Rapid Acting Insulin Market

by Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), Indication (Type 1 Diabetes and Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2020-2027

Report Code: A10599
Pages: 168
Mar 2021 | 4505 Views
Author(s) : Sayali S, Smita N , Onkar S
Tables: 101
Charts: 16
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Rapid Acting Insulin Market

Request Now !

The global rapid acting insulin market size was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027. 

Patients with different health issues such as respiratory disease and diabetes are at higher risk of getting affected by this covid-19 virus. It is found that the mortality rate is high in a patient with diabetes compared to the general population. Without or irregular supply of rapid acting insulin a person with diabetes will die within a few days. To overcome this situation the insulin manufacturing companies are taking different steps to make the product available to the patients, which drives the market growth in near future. On the side, there is no supply shortage of rapid acting insulin but the use of insulin is get reduced.

Rapid acting insulin is one of the fastest acting insulin that starts working within 15 minutes of its introduction. Action of this insulin is supposed to last for 5 hours. Some of the rapid acting insulin available in the market are Humalog, Fiasp, NovoRapid, Apidra and others. 

Rapid-Acting-Insulin-Market,-2020-2027

The COVID-19 outbreak that started from Wuhan city of China has now wide spread globally. Almost every nation is dealing with the outbreak. Furthermore, most of the markets have observed a drop down, owing to the lockdown situation declared by the government of various countries. However, the outbreak of COVID-19 is expected to contribute to the growth opportunities for industries wherein the treatment and management of chronic conditions are carried out. According to an article by the American Diabetes Association in 2020, people with diabetes are more likely to have serious complications from COVID-19. Furthermore, having heart disease or other complications in addition to diabetes could worsen the chance of getting seriously ill from COVID-19 as more than one condition makes it harder for patients to fight the infection. This helped major players to adopt various strategies to gain maximum share during the COVID-19 outbreak. For instance, in April 2020, in response to the emergency caused by COVID-19, Eli Lilly and Company introduced the Lilly Insulin Value Program. This program allows anyone with commercial insurance and those without insurance at all to fill their monthly prescription of Lilly insulin for $35. Furthermore, the program became effective from the given date and covered most Lilly insulin, including all Humalog (insulin lispro injection 100 units/mL) formulations. On the side, there is no supply shortage of rapid acting insulin.

The growth of the global rapid acting insulin market is majorly driven by the surge in prevalence of diabetes worldwide, increase in investment in research and development (R&D) for human recombinant insulin is expected to drive the need for insulin used in management of diabetes thereby boosting the growth of the market. Furthermore, sedentary & unhealthy lifestyles double the risk of diabetes, because of overweight or obesity, an unhealthy diet and physical inactivity, which account for about 80% of the increase in prevalence of diabetes. However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population in developing regions are expected to provide lucrative growth opportunities for the rapid acting insulin market growth.

The global rapid acting insulin market is segmented on the basis of product type, indication, distribution channel, and region. By product type, the market is segregated into insulin lispro, insulin aspart, and insulin glulisine. Depending on indication, it is fragmented into type 1 diabetes and type 2 diabetes. Furthermore, the market is divided on the basis of distribution channel into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segmental review

By product type, the insulin lispro segment is anticipated to grow with the largest rapid acting insulin market share over the forecast period. This is attributed to better advantages posed by the product, which include faster subcutaneous absorption, earlier & greater insulin peak, and shorter duration of action. This contributes to help the industry generate higher revenue through insulin lispro.

Rapid Acting Insulin Market
By Product Type

Your browser does not support the canvas element.

Insulin Lispro is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

By indication, the type 2 diabetes segment occupied the largest share of the market, owing to rise in urbanization, unhealthy diet, and reduced physical activity leads to rise in the number of people with type 2 diabetes which will further boost the rapid acting insulin market growth.

Rapid Acting Insulin Market
By Indication

Your browser does not support the canvas element.

Type 2 Diabetes holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By distribution channel, the drug stores & retail pharmacies segment occupied the largest share of the market, owing to availability of drug store & retail pharmacy stores everywhere. In addition these pharmacies provide alternate options for insulin, if the ones prescribed are not available. 

Rapid Acting Insulin Market
By Region

2027
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 4.1% during 2020-2027.

Get more information on this report : Request Sample Pages

North America accounted for the largest share of revenue in 2019, and is anticipated to maintain its dominance from 2020 to 2027 due to increasing incidences of diabetes and geriatric population, thereby driving the region’s rapid acting insulin market. On the other side, Asia-Pacific is expected to register the highest CAGR in the rapid acting insulin market in future, owing to westernized lifestyle behaviors and the increased prevalence of obesity. This is expected to boost the rapid acting insulin market over the forecast period.

Some of the key players operating in the rapid acting insulin market include ADOCIA SAS, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals, Geropharm LLC, Mannkind Corporation, Novo Nordisk A/S, Sanofi S.A., and Wockhadt Ltd.

Key Benefits For Stakeholders

  • This report entails a detailed quantitative analysis along with the current global rapid acting insulin market trends from 2020 to 2027 to identify the prevailing opportunities along with the strategic assessment.
  • The rapid acting insulin market forecast is studied from 2020 to 2027.
  • The rapid acting insulin market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global rapid acting insulin market.

Rapid Acting Insulin Market Report Highlights

Aspects Details
By Product Type
  • Lispro Insulin
  • Aspart Insulin
  • Glulisine Insulin
By Indication
  • Type 1 Diabetes
  • Type 2 Diabetes
By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers
By Region
  • North America  (U.S, Canada, Mexico)
  • Europe  (Germany, Uk, France, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, Australia, India, Rest of Asia-Pacific)
  • LAMEA  (Latin America, Middle East & Africa)
Key Market Players Mannkind Corporation, ADOCIA SAS, Sanofi S.A., Geropharm LLC, Eli Lilly And Company, Novo Nordisk A/S, Gan & Lee Pharmaceuticals, Biocon Limited, Wockhadt Ltd.
 

Loading Table Of Content...


 
 

In accordance to several interviews conducted, the rapid acting insulin market is expected to witness a significant growth owing to sedentary & unhealthy lifestyles increase all causes of mortality, double the risk of diabetes, because of overweight or obesity, an unhealthy diet and physical inactivity, which account for about 80% of the increase in prevalence of diabetes.

Furthermore, surge in prevalence of diabetes worldwide is the major factor that contributes toward growth of the rapid acting insulin market. In addition increase in government expenditure on healthcare also propel the market growth.

Increasing incidences of diabetes and geriatric population, are anticipated to drive the growth in North America On the other side, Asia-Pacific is expected to register the highest CAGR in the rapid acting insulin market in future, owing to westernized lifestyle behaviors and the increased prevalence of diabetes. This is expected to boost the rapid acting insulin market over the forecast period.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of Rapid Acting Insulin Market is $7,100.4million in 2019.

A. The forcast period for Rapid Acting Insulin Market is 2020 to 2027

A. The market value of Rapid Acting Insulin Market in 2020 is $6,736.9 million.

A. The base year is 2019 in Rapid Acting Insulin Market

A. Top companies such as, ADOCIA SAS, Biocon Limited, Eli Lilly And Company, Gan & Lee Pharmaceuticals, Geropharm LLC, Mannkind Corporation, Novo Nordisk A/S, Sanofi S.A., and Wockhadt Ltd. held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in regions.

A. Lispro, product type segment is the most influencing segment, owing to the better advantages posed by the product, which includes faster subcutaneous absorption, an earlier and greater insulin peak, and a shorter duration of action, which is driving the growth of the global Rapid acting insulin market

A. The major factor that fuels the growth of the rapid acting insulin market includes, the surge in the availability of continuous glucose monitoring. Furthermore, the sedentary, unhealthy lifestyle adapted by the population due to increase in working population would contribute to market growth. The family diabetic history, however is also a major factor causing the surge in demand for rapid acting insulin. In addition to this, the steep rise in the research and development in the human recombinant insulin would propel the growth of the market are expected to boost the market growth.

A. North America accounted for the largest share of revenue in 2019, and is anticipated to maintain its dominance from 2020 to 2027, owing to increasing incidences of diabetes and geriatric population. However, Asia-Pacific is expected to grow at the highest CAGR, owing to favorable government policies and increasing R&D initiatives by key manufacturers.

A. Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose (or blood sugar), which leads over time to serious damage to the heart, blood vessels, eyes, kidneys and nerves. 

A. Rapid-acting insulin, is a type of synthetic (man-made) insulin which is injectable and is prescribed for people with diabetes to help control blood glucose (blood sugar) levels. It is absorbed into the bloodstream within minutes,to mimic the action of bolus insulin, the surge of insulin released by the pancreas in response to the ingestion of food.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS

Purchase Full Report of
Rapid Acting Insulin Market

Start reading instantly.
This Report and over 54,639+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Mar 2022 - Mar 2023)
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2022 - Mar 2023)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2022 - Mar 2023)
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2022 - Mar 2023)
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2022 - Mar 2023)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers